#Shanghai #United States #Qiming Venture Partners #Attovia Therapeutics #ATTOBODY

Attovia Therapeutics Makes a Mark on Nasdaq

On August 5, 2026, Attovia Therapeutics, a biopharmaceutical company specializing in immune-mediated disease therapeutics, officially debuted on Nasdaq under the ticker symbol ATTO. This pivotal moment came as the company offered its shares at an initial price of $17.00, which quickly rose to $21.00 upon market opening, achieving an impressive market capitalization of approximately $904 million within hours.

A Vision for Innovative Therapies

Founded in 2023, Attovia is dedicated to developing biotherapeutics for conditions with significant unmet medical needs. The company's innovative approach leverages its proprietary ATTOBODY biologics platform, a technology licensed globally from Alamar Biosciences, another company within the Qiming Venture Partners portfolio. This platform is designed to revolutionize the discovery of therapeutic candidates. By employing an evolution-based high-throughput workflow, Attovia can swiftly generate a wide array of biologic candidates. These can then be fine-tuned to create monospecific, bispecific, and trispecific biologics.

Nominated Candidates and Investment Plans

As part of its growth strategy, Attovia has identified three primary product candidates—ATTO-1310, ATTO-2306, and ATTO-1091. The proceeds from the IPO are crucial to advancing the clinical development of these candidates, as highlighted in the company’s prospectus. The funding will also support further research into the candidate pipeline.

Dr. Kan Chen, Partner and Healthcare Co-Lead at Qiming Venture Partners, expressed optimism about the potential impact of Attovia’s therapies. He stated that “immune-mediated diseases affect large patient populations worldwide and substantial unmet clinical needs persist with current standard-of-care therapies.” He emphasized the importance of Attovia's unique ATTOBODY platform, which offers a robust framework for creating complex biologics tailored to these needs.

Long-Term Commitment to Innovation

Qiming Venture Partners, the backing firm for Attovia, has a longstanding history of investing in pioneering biotech firms. With around $9.5 billion raised since its inception in 2006, Qiming has nurtured over 580 innovative companies across diverse sectors including technology and healthcare. Notably, more than 210 of its portfolio companies have successfully gone public via major exchanges, showcasing the firm’s effective investment strategy.

Attovia’s success is not just a win for the company but also a testament to Qiming’s commitment to advancing biotechnological innovations that aim to enhance patient outcomes globally. As the company prepares for its next steps in clinical development, it stands poised to deliver transformative therapies that could redefine standard care for those suffering from immune-mediated diseases.

Conclusion

The launch of Attovia Therapeutics on Nasdaq signifies a promising leap into the future of medicine, specifically in the field of immune-mediated diseases. With the support from Qiming Venture Partners and a solid clinical pipeline backed by cutting-edge technology, Attovia is on the verge of changing the landscape of biopharmaceutical treatments. As they move forward, the industry eagerly anticipates the outcomes of their innovative therapeutics.

• ---